Posted by Michael Wonder on 14 May 2018
Price cuts secure NHS place for MS drugs
14 May 2018 - NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis (RRMS) after price cuts enabled the cost regulator to endorse their routine use on the NHS.
The Institute has published draft guidelines recommending Novartis’ Extavia (interferon beta-1b), Teva’s Copaxone (glatiramer acetate), Biogen Idec’s Avonex (interferon beta-1a) and Merck Serono’s Rebif (interferon beta-1a) as treatment options.
Previous draft guidance issued in December last year recommended only Extavia, but following price reductions on the other three the Committee concluded that they could also be considered value for money for the NHS.
